Literature DB >> 25788031

The more we use, the more we lose.

Ali Alkan1, Dılşa Mızrak, Güngör Utkan.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25788031     DOI： 10.1007/s12032-015-0569-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

1.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

Authors:  Henri Roché; Pierre Fumoleau; Marc Spielmann; Jean-Luc Canon; Thierry Delozier; Daniel Serin; Michel Symann; Pierre Kerbrat; Patrick Soulié; Françoise Eichler; Patrice Viens; Alain Monnier; Anita Vindevoghel; Mario Campone; Marie-Josèphe Goudier; Jacques Bonneterre; Jean-Marc Ferrero; Anne-Laure Martin; Jean Genève; Bernard Asselain
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.

Authors:  Icro Meattini; Giulio Francolini; Vieri Scotti; Carla De Luca Cardillo; Sabrina Cappelli; Fiammetta Meacci; Ilaria Francesca Furfaro; Cristina Muntoni; Silvia Scoccianti; Beatrice Detti; Monica Mangoni; Jacopo Nori; Lorenzo Orzalesi; Massimiliano Fambrini; Simonetta Bianchi; Lorenzo Livi
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

3.  Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Authors:  Miguel Martín; Alvaro Rodríguez-Lescure; Amparo Ruiz; Emilio Alba; Lourdes Calvo; Manuel Ruiz-Borrego; Blanca Munárriz; César A Rodríguez; Carmen Crespo; Enrique de Alava; José Antonio López García-Asenjo; María Dolores Guitián; Sergio Almenar; Jesús Fernando González-Palacios; Francisco Vera; José Palacios; Manuel Ramos; Jose Manuel Gracia Marco; Ana Lluch; Isabel Alvarez; Miguel Angel Seguí; José Ignacio Mayordomo; Antonio Antón; José Manuel Baena; Arrate Plazaola; Alfonso Modolell; Amadeu Pelegrí; Jose Ramón Mel; Enrique Aranda; Encarna Adrover; José Valero Alvarez; José Luis García Puche; Pedro Sánchez-Rovira; Sonia Gonzalez; José Manuel López-Vega
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.